U.S. Online Retail and Ecommerce Stock News

NYSE:ALIT
NYSE:ALITProfessional Services

Is Alight a Bargain After 60% Drop and New Employee Benefits Partnerships?

Ever wondered if Alight could be a hidden gem or is already priced to perfection? If you’re on the hunt for value, you might be surprised by what the numbers reveal. It's been a rollercoaster for Alight’s shareholders. They have seen the stock drop 12.3% in the last week and a staggering 60.0% since the start of the year, signaling a big shift in how the market values the business. Recently, Alight made headlines by entering new partnerships that aim to strengthen its position in the...
NasdaqGS:CTMX
NasdaqGS:CTMXBiotechs

Will CytomX Therapeutics' (CTMX) CX-801 Data Deepen Confidence in Its Immunotherapy Platform?

CytomX Therapeutics announced it will present initial translational data from its ongoing Phase 1 study of CX-801 in advanced melanoma at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, MD. This upcoming clinical update provides stakeholders with a key opportunity to assess the potential of CytomX's immunotherapy pipeline, possibly shaping future expectations around its development progress and clinical...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

BioNTech (BNTX) Net Losses Rise 22.1% Annually, Challenging Bullish Pipeline Narratives

BioNTech (BNTX) remains unprofitable, with net losses increasing at an annual rate of 22.1% over the past five years. While revenue is projected to grow just 1.7% per year, which is much slower than the broader US market's 10.5% rate, the company is expected to stay in the red for at least the next three years. Investors may take note of BioNTech trading below analyst price targets, but persistent weak margins and muted growth expectations continue to cloud the overall outlook. See our full...
NasdaqGS:SPSC
NasdaqGS:SPSCSoftware

Has the 25% Drop Made SPS Commerce a Bargain or a Risk for 2025?

Wondering if SPS Commerce is a hidden bargain or a value trap? Here is a breakdown of what’s going on with this software stock before you decide whether it deserves a spot on your radar. The stock has caught plenty of attention after plunging by 25.6% this week and over 54% year-to-date. You may be wondering if this volatility hints at risk, opportunity, or both. Recent news around sector-wide shifts in software demand and emerging competitive pressures have added fuel to the fire. Investors...
NYSE:SEE
NYSE:SEEPackaging

How Investors May Respond To Sealed Air (SEE) Surging Profitability Amid Flat Sales in Q3

Sealed Air Corporation recently reported third-quarter 2025 earnings, highlighting a substantial increase in net income to US$255.1 million and diluted earnings per share to US$1.73, compared to the same period last year, with sales remaining largely unchanged at US$1.35 billion. This performance suggests operational efficiencies are compensating for flat revenue, as the company also reaffirmed its full-year earnings guidance despite continued volume pressures in several segments. We’ll...
NasdaqGS:HTZ
NasdaqGS:HTZTransportation

Does the Recent 69.8% Hertz Stock Surge Signal a Real Opportunity for 2025?

Curious if Hertz Global Holdings is a bargain or a bounce trap? You're not alone, and we're diving deep to see just how much value might be hiding in the numbers. The stock has rocketed up 32.4% year to date and gained an impressive 69.8% over the past year, even though it has dipped 4.4% in the last week and 21.0% over the past month. Momentum has largely been sparked by renewed attention on the used car market and shifting consumer travel habits, both of which put Hertz in the spotlight...
NYSE:HRTG
NYSE:HRTGInsurance

How Investors May Respond To Heritage Insurance Holdings (HRTG) Earnings-Revenue Divergence and Estimate Revisions

Heritage Insurance Holdings Inc will report its Q3 2025 earnings on November 5, 2025, following a quarter where its actual earnings per share significantly surpassed analyst expectations even as revenue came in below estimates. This divergence between stronger-than-expected earnings and softer revenue projections, alongside upward earnings estimate revisions and declining revenue forecasts for 2025 and 2026, has driven increased investor attention ahead of the upcoming results. We will...
NYSE:TE
NYSE:TEElectrical

3 Growth Companies With High Insider Ownership And Up To 111% Earnings Growth

In the current U.S. market landscape, major stock indexes have experienced a pullback, with tech shares leading the decline despite some companies posting strong quarterly results. Amidst this backdrop of fluctuating indices and economic uncertainty, identifying growth companies with high insider ownership can be crucial for investors seeking potential resilience and alignment of interests between management and shareholders.
NasdaqGS:GDRX
NasdaqGS:GDRXHealthcare Services

Will GoodRx Holdings' (GDRX) Leadership Shift Shape Its Next Chapter or Signal Strategic Uncertainty?

GoodRx Holdings announced that Trevor Bezdek, Co-Chairman of the Board, ended his employment and executive officer role as of November 1, 2025, and will stay on as a non-employee director; this coincides with the company's scheduled Q3 2025 earnings release on November 4. This combination of executive transition and earnings anticipation introduces new uncertainty about GoodRx's future leadership direction and financial outlook. We'll examine how the departure of an executive officer may...
NasdaqGM:RANI
NasdaqGM:RANIPharmaceuticals

Why Rani Therapeutics (RANI) Is Up 23.6% After Promising Oral Semaglutide Preclinical Data Release

Rani Therapeutics Holdings announced it would present preclinical data on its RaniPill® oral delivery platform at ObesityWeek® 2025, highlighting that oral semaglutide (RT-116) in dogs is bioequivalent to subcutaneous injections and produces similar weight loss. This research could generate interest, as it demonstrates the potential for the RaniPill to enable oral delivery of peptide drugs traditionally administered via injection. We'll examine how these promising preclinical results for...
NasdaqGS:PACB
NasdaqGS:PACBLife Sciences

A Fresh Look at PacBio’s (PACB) Valuation Following ARK Invest’s Major Share Purchase

Pacific Biosciences of California (PACB) shares jumped after news broke that ARK Investment Management, led by Cathie Wood, had acquired over one million shares. This high-profile buy is increasing investor attention and speculation around PacBio’s DNA sequencing technology and its growth outlook. See our latest analysis for Pacific Biosciences of California. ARK’s sizeable buy-in comes as PacBio’s share price has staged a sharp reversal. After months of drifting, the past 30 days saw a...
NasdaqGS:MSEX
NasdaqGS:MSEXWater Utilities

Middlesex Water (MSEX): Assessing Valuation After Q3 Earnings Miss and Dividend Hike

Middlesex Water (MSEX) shares have recently responded to third quarter earnings results that missed consensus expectations. Both revenue and earnings per share came in below forecasts amid softer water consumption. See our latest analysis for Middlesex Water. The disappointing third quarter results put immediate pressure on Middlesex Water’s share price, which slid more than 13% in a single day. While the company marked its 53rd consecutive dividend increase and announced a new utility...
NasdaqGS:MGRC
NasdaqGS:MGRCTrade Distributors

Should Softer Earnings and Revised Outlook Require Action From McGrath RentCorp (MGRC) Investors?

McGrath RentCorp recently reported its third-quarter 2025 earnings, revealing a year-over-year decline in sales and net income, and updated its full-year 2025 revenue guidance to a range of US$935 million to US$955 million. Institutional investor activity and the announcement of a quarterly dividend highlight continued shareholder engagement, even as profitability metrics from core operations moderated versus the prior year. We'll examine how McGrath RentCorp's updated guidance amid softer...
NasdaqGM:FRPT
NasdaqGM:FRPTFood

Freshpet (FRPT) Margin Surge Reinforces Bullish Narratives Despite One-Time $18.4M Loss

Freshpet (FRPT) delivered a notable performance with profit margins hitting 11.4%, up from 4.8% last year, and becoming profitable across the past five years with annual earnings growth averaging 41.8%. Most recently, the company's earnings climbed 180%, marking a sharp acceleration over earlier periods and highlighting a strong upswing in profitability. While forecasts point to continued revenue and earnings growth at 10% and 14% per year, respectively, both figures are set to trail just...